Exact Sciences (EXAS) Financials

$51.55 +4.39 (+9.31%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$51.68 +0.13 (+0.24%)

As of 05/2/2025 07:50 PM Eastern

Annual Income Statements for Exact Sciences

This table shows Exact Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-158	-167	-114	-175	-213	-824	-596	-624	-204	-1,029
Consolidated Net Income / (Loss)	-158	-167	-114	-175	-213	-824	-596	-624	-204	-1,029
Net Income / (Loss) Continuing Operations	-158	-167	-114	-175	-213	-824	-596	-624	-204	-1,029
Total Pre-Tax Income	-158	-167	-115	-175	-406	-829	-843	-633	-202	-1,036
Total Operating Income	-159	-169	-118	-159	-234	-768	-856	-594	-215	-1,049
Total Gross Profit	15	54	188	338	660	1,137	1,308	1,423	1,762	1,919
Total Revenue	39	99	266	454	876	1,491	1,767	2,084	2,500	2,759
Operating Revenue	39	99	266	454	876	1,491	1,767	2,084	2,500	2,759
Total Cost of Revenue	25	45	78	117	217	354	459	661	738	840
Operating Cost of Revenue	25	45	78	117	217	354	459	661	738	840
Total Operating Expenses	174	223	306	497	893	1,905	2,164	2,016	1,977	2,967
Selling, General & Admin Expense	58	77	109	178	352	481	801	663	800	782
Marketing Expense	82	113	154	249	385	590	862	930	828	894
Research & Development Expense	34	33	42	67	140	554	386	394	427	431
Other Operating Expenses / (Income)	-	-	-	0.00	0.00	-24	0.00	13	-78	-9.20
Impairment Charge	-	-	-	0.00	0.00	210	20	16	0.62	869
Total Other Income / (Expense), net	1.27	1.81	3.73	-16	-173	-61	13	-39	13	13
Interest Expense	0.01	0.21	0.21	37	199	68	19	20	19	27
Other Income / (Expense), net	-	-	-	-	-	6.57	32	-19	-	40
Income Tax Expense	-	-	-0.19	0.09	-193	-5.46	-247	-9.06	2.40	-7.30
Basic Earnings per Share	($1.71)	($1.63)	($0.99)	($1.43)	($1.62)	($5.45)	($3.48)	($3.54)	($1.13)	($5.59)
Weighted Average Basic Shares Outstanding	92.14M	102.34M	115.68M	122.21M	131.26M	151.14M	171.35M	176.35M	180.14M	184.20M
Diluted Earnings per Share	($1.71)	($1.63)	($0.99)	($1.43)	($1.62)	($5.45)	($3.48)	($3.54)	($1.13)	($5.59)
Weighted Average Diluted Shares Outstanding	92.14M	102.34M	115.68M	122.21M	131.26M	151.14M	171.35M	176.35M	180.14M	184.20M
Weighted Average Basic & Diluted Shares Outstanding	92.14M	102.34M	115.68M	122.21M	131.26M	151.14M	178.22M	-	181.53M	185.76M

This table shows Exact Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-149	-128	-74	-81	0.79	-50	-110	-16	-38	-865
Consolidated Net Income / (Loss)	-149	-128	-74	-81	0.79	-50	-110	-16	-38	-865
Net Income / (Loss) Continuing Operations	-149	-128	-74	-81	0.79	-50	-110	-16	-38	-865
Total Pre-Tax Income	-152	-130	-72	-80	1.04	-50	-108	-14	-37	-876
Total Operating Income	-138	-119	-77	-77	6.85	-68	-107	-26	-39	-876
Total Gross Profit	375	319	446	465	460	392	467	509	513	429
Total Revenue	523	553	602	622	628	647	638	699	709	713
Operating Revenue	523	553	602	622	628	647	638	699	709	713
Total Cost of Revenue	148	234	157	157	169	255	170	190	196	284
Operating Cost of Revenue	148	234	157	157	169	255	170	190	196	284
Total Operating Expenses	513	438	523	542	453	460	574	536	552	1,306
Selling, General & Admin Expense	192	120	217	238	217	128	243	202	217	120
Marketing Expense	188	294	187	176	173	291	192	185	195	322
Research & Development Expense	91	95	95	104	111	116	111	121	100	100
Other Operating Expenses / (Income)	13	-	0.00	0.00	-72	-6.40	0.27	-3.80	-3.10	-2.57
Impairment Charge	5.95	3.43	0.07	0.55	0.00	-	4.45	8.15	19	838
Total Other Income / (Expense), net	-14	-11	4.60	-2.99	-5.81	17	-1.73	12	1.98	0.39
Interest Expense	5.24	5.41	-4.11	7.82	7.87	7.87	7.94	-0.11	9.61	9.58
Income Tax Expense	-3.12	-2.18	1.66	1.11	0.25	-0.61	1.81	1.46	0.81	-11
Basic Earnings per Share	($0.84)	($0.72)	($0.42)	($0.45)	$0.00	($0.26)	($0.60)	($0.09)	($0.21)	($4.69)
Weighted Average Basic Shares Outstanding	177.00M	176.35M	178.57M	180.20M	180.65M	180.14M	182.35M	184.31M	184.80M	184.20M
Weighted Average Diluted Shares Outstanding	177.00M	176.35M	180.85M	180.20M	184.08M	180.14M	184.53M	184.31M	184.80M	184.20M
Weighted Average Basic & Diluted Shares Outstanding	177.68M	0.00	180.85M	-	-	181.53M	184.53M	184.77M	185.08M	185.76M

This table details how cash moves in and out of Exact Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-17	7.79	29	83	17	1,314	-1,176	-73	367	-3.04
Net Cash From Operating Activities	-134	-130	-72	-69	-112	136	-102	-224	156	211
Net Cash From Continuing Operating Activities	-134	-130	-72	-69	-112	136	-102	-224	156	211
Net Income / (Loss) Continuing Operations	-158	-167	-114	-175	-213	-824	-596	-624	-204	-1,029
Consolidated Net Income / (Loss)	-158	-167	-114	-175	-213	-824	-596	-624	-204	-1,029
Depreciation Expense	7.60	11	15	21	34	70	85	100	114	120
Amortization Expense	0.94	-0.30	-0.55	29	14	96	95	97	92	95
Non-Cash Adjustments To Reconcile Net Income	17	25	36	58	300	843	449	297	173	1,094
Changes in Operating Assets and Liabilities, net	-1.85	1.45	-7.79	-0.91	-247	-49	-136	-95	-19	-69
Net Cash From Investing Activities	-65	-12	-161	-782	-124	-702	-1,082	74	50	-442
Net Cash From Continuing Investing Activities	-65	-12	-161	-782	-124	-702	-1,082	74	50	-442
Purchase of Property, Plant & Equipment	-20	-15	-48	-150	-173	-476	-194	-214	-125	-181
Acquisitions	-1.90	-	-24	-18	-974	-6.66	-500	-15	-52	0.00
Purchase of Investments	-205	-190	-357	-1,193	-634	-1,106	-1,182	-174	-156	-467
Sale of Property, Plant & Equipment	-	-	-	-	-	0.00	0.00	25	0.00	0.00
Sale and/or Maturity of Investments	162	193	271	579	1,657	887	794	453	383	206
Other Investing Activities, net	-	-	-3.07	-0.58	-1.00	0.35	-0.74	-0.55	0.25	-0.23
Net Cash From Financing Activities	182	150	261	934	253	1,880	8.47	76	160	232
Net Cash From Continuing Financing Activities	182	150	261	934	253	1,880	8.47	76	160	232
Repayment of Debt	-	-	-0.20	0.00	-493	-151	-29	0.00	0.00	-68
Issuance of Debt	5.47	-	0.00	923	729	1,124	0.00	44	128	267
Issuance of Common Equity	177	150	261	12	17	907	38	32	32	33
Effect of Exchange Rate Changes	0.01	-0.22	-	-	0.00	0.00	0.02	0.03	1.32	-3.29
Cash Interest Paid	0.10	0.21	0.20	4.64	5.13	9.38	11	12	19	28

This table details how cash moves in and out of Exact Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	22	7.19	179	183	-9.75	15	-258	184	59	12
Net Cash From Operating Activities	-41	52	-38	100	24	70	-82	107	139	47
Net Cash From Continuing Operating Activities	-41	52	-38	100	24	70	-82	107	139	47
Net Income / (Loss) Continuing Operations	-149	-128	-74	-81	0.79	-50	-110	-16	-38	-865
Consolidated Net Income / (Loss)	-149	-128	-74	-81	0.79	-50	-110	-16	-38	-865
Depreciation Expense	25	27	27	28	29	31	31	30	30	29
Amortization Expense	24	23	23	23	23	23	23	23	24	24
Non-Cash Adjustments To Reconcile Net Income	89	63	51	73	5.20	44	75	53	73	893
Changes in Operating Assets and Liabilities, net	-30	67	-65	58	-34	21	-101	16	49	-34
Net Cash From Investing Activities	65	-58	83	66	-33	-67	-171	-147	-82	-42
Net Cash From Continuing Investing Activities	66	-58	83	66	-33	-67	-171	-147	-82	-42
Purchase of Property, Plant & Equipment	-45	-73	-29	-35	-25	-35	-38	-36	-26	-81
Acquisitions	1.37	-15	-	-	-	-2.41	-	-	-	45
Purchase of Investments	-23	-45	-9.03	-48	-25	-75	-178	-148	-81	-60
Sale and/or Maturity of Investments	108	76	121	149	67	46	44	36	71	55
Net Cash From Financing Activities	0.24	10	134	16	0.09	10	-3.00	225	-0.23	10
Net Cash From Continuing Financing Activities	0.24	10	134	16	0.09	10	-3.00	225	-0.23	10
Repayment of Debt	-0.71	5.11	-5.34	-1.16	6.50	-	-1.59	-48	-	-18
Issuance of Debt	-	-5.53	138	-	-7.48	-2.27	0.00	254	-2.36	16
Issuance of Common Equity	0.94	11	-	-	-	15	-	-	-	13
Effect of Exchange Rate Changes	-2.43	3.21	0.55	0.06	-1.24	1.95	-1.14	-0.31	1.87	-3.72
Cash Interest Paid	5.62	0.77	6.44	0.94	11	0.60	11	1.18	9.14	6.73

This table presents Exact Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2022	12/31/2022	12/31/2023	12/31/2024
Total Assets	364	377	599	1,524	3,506	4,925	6,227	6,227	6,471	5,928
Total Current Assets	326	334	487	1,228	554	2,199	982	982	1,194	1,571
Cash & Equivalents	41	49	77	160	177	1,491	242	242	605	601
Short-Term Investments	266	262	347	964	146	349	390	390	172	437
Accounts Receivable	4.93	8.53	26	45	130	233	158	158	204	249
Inventories, net	6.68	6.83	26	39	62	92	118	118	127	162
Prepaid Expenses	7.38	7.11	10	19	38	33	74	74	86	122
Plant, Property, & Equipment, net	34	38	80	245	455	452	685	685	698	694
Total Noncurrent Assets	4.07	5.33	31	51	2,497	2,275	4,560	4,560	4,579	3,663
Goodwill	-	-	24	17	1,203	1,238	2,346	2,346	2,367	2,367
Intangible Assets	-	1.55	-	29	1,144	847	1,956	1,956	1,890	1,010
Other Noncurrent Operating Assets	4.07	3.78	7.15	4.42	150	190	258	258	321	287
Total Liabilities & Shareholders' Equity	364	377	599	1,524	3,506	4,925	6,227	6,227	6,471	5,928
Total Liabilities	37	42	78	843	1,218	2,690	3,184	3,184	3,326	3,526
Total Current Liabilities	27	31	68	136	236	633	413	413	515	732
Short-Term Debt	0.17	0.17	0.18	0.01	0.83	314	-	0.00	50	249
Accounts Payable	3.31	0.71	16	28	26	36	75	75	79	90
Accrued Expenses	22	28	49	101	193	234	299	299	342	328
Other Current Liabilities	1.00	1.70	2.68	7.38	16	50	39	39	44	65
Total Noncurrent Liabilities	10	11	10	707	981	2,056	2,771	2,771	2,811	2,794
Long-Term Debt	4.79	4.63	4.27	689	828	1,884	2,236	2,236	2,314	2,321
Capital Lease Obligations	1.06	0.69	-	-	119	121	182	182	161	157
Other Noncurrent Operating Liabilities	4.60	5.73	5.75	18	35	51	352	352	336	316
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	327	335	520	681	2,288	2,236	3,043	3,043	3,145	2,402
Total Preferred & Common Equity	327	335	520	681	2,288	2,236	3,043	3,043	3,145	2,402
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	327	335	520	681	2,288	2,236	3,043	3,043	3,145	2,402
Common Stock	906	1,082	1,382	1,718	3,408	4,281	6,313	6,313	6,613	6,901
Retained Earnings	-579	-746	-861	-1,036	-1,120	-2,046	-3,265	-3,265	-3,469	-4,498
Accumulated Other Comprehensive Income / (Loss)	-0.43	-0.42	-0.75	-1.42	-0.10	0.53	-5.24	-5.24	1.43	-0.94

This table presents Exact Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	12/31/2022	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	6,227	6,421	6,376	6,673	6,749
Total Current Assets	982	1,148	1,120	1,452	1,533
Cash & Equivalents	242	595	347	530	589
Short-Term Investments	390	140	305	417	432
Accounts Receivable	158	199	241	264	265
Inventories, net	118	133	129	127	137
Prepaid Expenses	74	82	99	114	110
Plant, Property, & Equipment, net	685	692	702	703	690
Total Noncurrent Assets	4,560	4,580	4,554	4,518	4,525
Goodwill	2,346	2,367	2,367	2,367	2,367
Intangible Assets	1,956	1,913	1,867	1,843	1,864
Other Noncurrent Operating Assets	258	300	320	307	293
Total Liabilities & Shareholders' Equity	6,227	6,421	6,376	6,673	6,749
Total Liabilities	3,184	3,300	3,244	3,481	3,538
Total Current Liabilities	413	477	685	669	724
Short-Term Debt	0.00	50	299	249	249
Accounts Payable	75	74	60	53	98
Accrued Expenses	299	310	265	303	314
Other Current Liabilities	39	43	61	64	63
Total Noncurrent Liabilities	2,771	2,823	2,559	2,812	2,814
Long-Term Debt	2,236	2,313	2,067	2,318	2,319
Capital Lease Obligations	182	168	162	168	163
Other Noncurrent Operating Liabilities	352	342	329	327	332
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	3,043	3,121	3,133	3,192	3,211
Total Preferred & Common Equity	3,043	3,121	3,133	3,192	3,211
Preferred Stock	0.00	0.00	0.00	0.00	0.00
Total Common Equity	3,043	3,121	3,133	3,192	3,211
Common Stock	6,313	6,542	6,713	6,789	6,839
Retained Earnings	-3,265	-3,419	-3,579	-3,595	-3,633
Accumulated Other Comprehensive Income / (Loss)	-5.24	-1.54	-0.50	-0.94	4.63

This table displays calculated financial ratios and metrics derived from Exact Sciences' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	2,093.38%	151.99%	167.66%	70.86%	92.82%	70.19%	18.49%	17.95%	19.93%	10.37%
EBITDA Growth	-56.34%	-4.97%	34.00%	-5.69%	-68.12%	-220.93%	-8.22%	35.46%	97.98%	-9,351.29%
EBIT Growth	-58.22%	-6.25%	30.00%	-34.79%	-46.60%	-225.57%	-8.25%	25.61%	64.92%	-369.34%
NOPAT Growth	-58.22%	-6.25%	30.00%	-34.79%	-46.60%	-228.38%	-11.46%	30.64%	63.77%	-387.74%
Net Income Growth	-57.73%	-5.96%	31.59%	-53.11%	-21.66%	-286.51%	27.68%	-4.68%	67.26%	-403.97%
EPS Growth	-36.80%	4.68%	39.26%	-44.44%	-13.29%	-236.42%	36.15%	-1.72%	68.08%	-394.69%
Operating Cash Flow Growth	-64.52%	2.95%	44.86%	3.88%	-61.96%	222.24%	-174.91%	-118.67%	169.83%	34.86%
Free Cash Flow Firm Growth	-73.68%	4.71%	-25.64%	-67.98%	-998.77%	87.96%	-696.92%	84.69%	48.51%	131.48%
Invested Capital Growth	179.25%	14.22%	237.36%	145.63%	1,083.51%	-6.76%	77.91%	0.00%	1.31%	-16.38%
Revenue Q/Q Growth	48.70%	26.51%	24.40%	13.93%	21.09%	12.93%	0.42%	3.95%	3.90%	2.47%
EBITDA Q/Q Growth	-4.68%	1.93%	13.16%	-13.77%	-49.73%	-84.86%	25.54%	18.73%	86.90%	-3,167.46%
EBIT Q/Q Growth	-5.18%	1.58%	11.07%	-19.77%	-25.01%	-69.59%	21.47%	11.94%	19.18%	-320.14%
NOPAT Q/Q Growth	-5.18%	1.58%	11.07%	-19.77%	-25.01%	-71.06%	18.45%	14.74%	19.18%	-336.61%
Net Income Q/Q Growth	-5.02%	1.66%	11.87%	-22.53%	1.32%	-80.46%	24.92%	12.96%	27.64%	-380.69%
EPS Q/Q Growth	-1.79%	5.78%	13.16%	-22.22%	4.71%	-78.10%	29.27%	14.08%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.87%	2.37%	26.88%	-0.13%	-28.04%	61,302.69%	-403.01%	25.52%	12.63%	-9.65%
Free Cash Flow Firm Q/Q Growth	-5.49%	4.43%	-15.71%	-11.71%	-757.30%	86.60%	-0.33%	41.75%	-104.61%	101.32%
Invested Capital Q/Q Growth	14.35%	-1.64%	44.03%	18.94%	617.25%	3.10%	4.91%	0.00%	0.00%	-16.85%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	37.87%	54.52%	70.56%	74.33%	75.27%	76.24%	74.04%	68.27%	70.49%	69.55%
EBITDA Margin	-381.68%	-159.00%	-39.21%	-24.25%	-21.15%	-39.87%	-36.42%	-19.93%	-0.34%	-28.79%
Operating Margin	-403.35%	-170.08%	-44.48%	-35.09%	-26.68%	-51.48%	-48.42%	-28.48%	-8.60%	-38.01%
EBIT Margin	-403.35%	-170.08%	-44.48%	-35.09%	-26.68%	-51.03%	-46.62%	-29.41%	-8.60%	-36.58%
Profit (Net Income) Margin	-400.14%	-168.26%	-43.01%	-38.54%	-24.32%	-55.22%	-33.71%	-29.91%	-8.17%	-37.29%
Tax Burden Percent	100.00%	100.00%	99.84%	100.05%	52.43%	99.34%	70.70%	98.57%	101.19%	99.30%
Interest Burden Percent	99.20%	98.93%	96.85%	109.77%	173.86%	108.93%	102.26%	103.20%	93.83%	102.68%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-630.85%	-424.96%	-127.57%	-64.50%	-10.37%	-19.10%	-15.88%	-8.60%	-3.10%	-16.34%
ROIC Less NNEP Spread (ROIC-NNEP)	-614.84%	-408.83%	-118.86%	-49.64%	-62.81%	-71.02%	-15.58%	-20.25%	-6.13%	-33.49%
Return on Net Nonoperating Assets (RNNOA)	579.60%	374.46%	100.83%	35.34%	-3.99%	-17.31%	-6.69%	-11.89%	-3.50%	-20.75%
Return on Equity (ROE)	-51.25%	-50.51%	-26.74%	-29.16%	-14.35%	-36.41%	-22.57%	-20.49%	-6.60%	-37.09%
Cash Return on Invested Capital (CROIC)	-725.38%	-438.23%	-236.11%	-148.77%	-179.20%	-12.11%	-71.95%	-8.60%	-4.40%	1.50%
Operating Return on Assets (OROA)	-47.00%	-45.61%	-24.25%	-15.03%	-9.30%	-18.06%	-14.78%	-9.84%	-3.39%	-16.28%
Return on Assets (ROA)	-46.63%	-45.13%	-23.45%	-16.50%	-8.47%	-19.54%	-10.68%	-10.01%	-3.22%	-16.60%
Return on Common Equity (ROCE)	-51.25%	-50.51%	-26.74%	-29.16%	-14.35%	-36.41%	-22.57%	-20.49%	-6.60%	-37.09%
Return on Equity Simple (ROE_SIMPLE)	-48.28%	-49.87%	-21.98%	-25.72%	-9.31%	-36.84%	-19.57%	-20.49%	-6.49%	-42.83%
Net Operating Profit after Tax (NOPAT)	-111	-118	-83	-112	-164	-537	-599	-415	-151	-734
NOPAT Margin	-282.34%	-119.05%	-31.14%	-24.56%	-18.68%	-36.03%	-33.90%	-19.93%	-6.02%	-26.61%
Net Nonoperating Expense Percent (NNEP)	-16.00%	-16.13%	-8.70%	-14.85%	52.45%	51.92%	-0.30%	11.65%	3.04%	17.15%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-7.61%	-2.65%	-14.31%
Cost of Revenue to Revenue	62.13%	45.48%	29.44%	25.67%	24.73%	23.76%	25.96%	31.73%	29.51%	30.45%
SG&A Expenses to Revenue	146.94%	77.38%	40.97%	39.17%	40.22%	32.28%	45.34%	31.83%	32.01%	28.34%
R&D to Revenue	86.00%	33.68%	15.83%	14.81%	15.94%	37.15%	21.82%	18.91%	17.08%	15.63%
Operating Expenses to Revenue	441.22%	224.60%	115.04%	109.42%	101.95%	127.72%	122.46%	96.74%	79.10%	107.56%
Earnings before Interest and Taxes (EBIT)	-159	-169	-118	-159	-234	-761	-824	-613	-215	-1,009
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-151	-158	-104	-110	-185	-595	-644	-415	-8.40	-794
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.72	4.32	12.09	11.39	5.25	8.91	4.41	2.89	4.25	4.33
Price to Tangible Book Value (P/TBV)	2.72	4.34	12.68	12.22	0.00	132.20	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	22.55	14.57	23.65	17.06	13.70	13.36	7.59	4.22	5.35	3.77
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	22.63	38.49	58.61	29.76	4.34	7.52	3.15	2.19	3.09	2.95
Enterprise Value to Revenue (EV/Rev)	14.92	11.50	22.07	16.11	14.41	13.68	8.60	5.08	6.05	4.38
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	149.54	0.00	0.00	96.89	57.42
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	179.52
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.02	0.02	0.01	1.01	0.41	1.04	0.79	0.79	0.80	1.14
Long-Term Debt to Equity	0.02	0.02	0.01	1.01	0.41	0.90	0.79	0.79	0.79	1.03
Financial Leverage	-0.94	-0.92	-0.85	-0.71	0.06	0.24	0.43	0.59	0.57	0.62
Leverage Ratio	1.10	1.12	1.14	1.77	1.69	1.86	2.11	2.05	2.05	2.24
Compound Leverage Factor	1.09	1.11	1.10	1.94	2.95	2.03	2.16	2.11	1.93	2.30
Debt to Total Capital	1.81%	1.61%	0.85%	50.30%	29.28%	50.92%	44.28%	44.28%	44.53%	53.17%
Short-Term Debt to Total Capital	0.05%	0.05%	0.03%	0.00%	0.03%	6.89%	0.00%	0.00%	0.88%	4.86%
Long-Term Debt to Total Capital	1.76%	1.56%	0.81%	50.30%	29.25%	44.02%	44.28%	44.28%	43.65%	48.31%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	98.19%	98.39%	99.15%	49.70%	70.72%	49.08%	55.72%	55.72%	55.47%	46.83%
Debt to EBITDA	-0.04	-0.03	-0.04	-6.25	-5.11	-3.90	-3.76	-5.82	-300.49	-3.43
Net Debt to EBITDA	2.00	1.93	4.03	3.95	-3.36	-0.81	-2.78	-4.30	-207.96	-2.13
Long-Term Debt to EBITDA	-0.04	-0.03	-0.04	-6.25	-5.11	-3.37	-3.76	-5.82	-294.54	-3.12
Debt to NOPAT	-0.05	-0.05	-0.05	-6.17	-5.79	-4.32	-4.04	-5.82	-16.78	-3.72
Net Debt to NOPAT	2.70	2.58	5.07	3.90	-3.81	-0.89	-2.98	-4.30	-11.61	-2.30
Long-Term Debt to NOPAT	-0.05	-0.05	-0.05	-6.17	-5.78	-3.73	-4.04	-5.82	-16.45	-3.38
Altman Z-Score	11.78	17.80	46.92	5.38	5.61	4.04	1.75	1.04	2.07	0.78
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	12.19	10.87	7.15	9.02	2.34	3.47	2.38	2.38	2.32	2.15
Quick Ratio	11.67	10.41	6.62	8.59	1.92	3.27	1.91	1.91	1.91	1.76
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-128	-122	-153	-257	-2,829	-341	-2,714	-415	-214	67
Operating Cash Flow to CapEx	-667.28%	-875.81%	-147.95%	-45.93%	-64.67%	28.64%	-52.74%	-118.00%	125.21%	116.33%
Free Cash Flow to Firm to Interest Expense	-21,338.77	-572.80	-744.09	-7.00	-14.20	-5.01	-145.86	-21.16	-11.00	2.49
Operating Cash Flow to Interest Expense	-22,336.17	-610.64	-348.17	-1.87	-0.56	2.01	-5.49	-11.39	8.03	7.79
Operating Cash Flow Less CapEx to Interest Expense	-25,683.50	-680.36	-583.51	-5.95	-1.43	-5.00	-15.91	-21.04	1.62	1.09
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.12	0.27	0.55	0.43	0.35	0.35	0.32	0.33	0.39	0.45
Accounts Receivable Turnover	12.50	14.77	15.22	12.67	9.98	8.20	9.03	13.19	13.82	12.19
Inventory Turnover	4.58	6.69	4.77	3.58	4.30	4.60	4.36	5.59	6.00	5.80
Fixed Asset Turnover	1.46	2.75	4.50	2.79	2.50	3.29	3.11	3.04	3.61	3.96
Accounts Payable Turnover	8.23	22.50	9.30	5.27	8.01	11.49	8.29	8.83	9.60	9.98
Days Sales Outstanding (DSO)	29.20	24.72	23.98	28.81	36.59	44.49	40.41	27.68	26.40	29.94
Days Inventory Outstanding (DIO)	79.66	54.55	76.58	101.97	84.95	79.31	83.75	65.27	60.80	62.96
Days Payable Outstanding (DPO)	44.36	16.22	39.26	69.27	45.57	31.77	44.01	41.35	38.04	36.58
Cash Conversion Cycle (CCC)	64.50	63.05	61.30	61.51	75.97	92.03	80.15	51.60	49.17	56.33
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	26	30	100	246	2,912	2,715	4,830	4,830	4,893	4,092
Invested Capital Turnover	2.23	3.57	4.10	2.63	0.56	0.53	0.47	0.43	0.51	0.61
Increase / (Decrease) in Invested Capital	17	3.70	70	146	2,666	-197	2,115	0.00	63	-801
Enterprise Value (EV)	588	1,143	5,870	7,320	12,630	20,409	15,198	10,584	15,127	12,089
Market Capitalization	889	1,448	6,291	7,755	12,007	19,930	13,412	8,797	13,379	10,399
Book Value per Share	$3.39	$3.09	$4.35	$5.54	$17.62	$14.86	$17.66	$17.13	$17.39	$12.98
Tangible Book Value per Share	$3.39	$3.08	$4.14	$5.16	($0.45)	$1.00	($7.31)	($7.09)	($6.15)	($5.26)
Total Capital	333	341	525	1,370	3,235	4,555	5,462	5,462	5,671	5,130
Total Debt	6.02	5.49	4.45	689	947	2,319	2,419	2,419	2,525	2,727
Total Long-Term Debt	5.85	5.32	4.27	689	946	2,005	2,419	2,419	2,475	2,478
Net Debt	-301	-306	-420	-435	623	479	1,786	1,786	1,748	1,689
Capital Expenditures (CapEx)	20	15	48	150	173	476	194	189	125	181
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-7.57	-8.05	-5.44	-32	-5.38	40	-63	-63	-48	50
Debt-free Net Working Capital (DFNWC)	299	303	419	1,092	318	1,880	570	570	730	1,088
Net Working Capital (NWC)	299	303	419	1,092	317	1,565	570	570	680	839
Net Nonoperating Expense (NNE)	46	49	32	64	49	286	-3.35	208	54	295
Net Nonoperating Obligations (NNO)	-301	-306	-420	-435	623	479	1,786	1,786	1,748	1,689
Total Depreciation and Amortization (D&A)	8.54	11	14	49	48	166	180	198	207	215
Debt-free, Cash-free Net Working Capital to Revenue	-19.20%	-8.10%	-2.05%	-7.10%	-0.61%	2.65%	-3.54%	-3.00%	-1.92%	1.83%
Debt-free Net Working Capital to Revenue	758.95%	304.96%	157.63%	240.26%	36.32%	126.03%	32.23%	27.32%	29.19%	39.45%
Net Working Capital to Revenue	758.53%	304.78%	157.56%	240.26%	36.23%	104.97%	32.23%	27.32%	27.19%	30.42%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.71)	($1.63)	($0.99)	($1.43)	($0.64)	($5.61)	$0.00	$0.00	($1.13)	($5.59)
Adjusted Weighted Average Basic Shares Outstanding	97.45M	110.60M	120.94M	125.76M	443.90M	169.09M	0.00	0.00	180.14M	184.20M
Adjusted Diluted Earnings per Share	($1.71)	($1.63)	($0.99)	($1.43)	($0.64)	($5.61)	$0.00	$0.00	($1.13)	($5.59)
Adjusted Weighted Average Diluted Shares Outstanding	97.45M	110.60M	120.94M	125.76M	443.90M	169.09M	0.00	0.00	180.14M	184.20M
Adjusted Basic & Diluted Earnings per Share	($1.71)	($1.63)	($0.99)	($1.43)	($0.64)	($5.61)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	92.14M	102.34M	115.68M	122.21M	131.26M	151.14M	0.00	0.00	181.53M	185.76M
Normalized Net Operating Profit after Tax (NOPAT)	-111	-118	-83	-112	-164	-391	-585	-404	-150	-125
Normalized NOPAT Margin	-282.34%	-119.05%	-31.14%	-24.56%	-18.68%	-26.19%	-33.10%	-19.40%	-6.00%	-4.55%
Pre Tax Income Margin	-400.14%	-168.26%	-43.08%	-38.52%	-46.38%	-55.59%	-47.68%	-30.35%	-8.07%	-37.56%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-26,511.33	-793.50	-574.32	-4.33	-1.17	-11.20	-44.28	-31.22	-11.06	-37.35
NOPAT to Interest Expense	-18,557.93	-555.45	-402.02	-3.03	-0.82	-7.91	-32.19	-21.16	-7.74	-27.17
EBIT Less CapEx to Interest Expense	-29,858.67	-863.23	-809.66	-8.41	-2.04	-18.22	-54.70	-40.87	-17.47	-44.05
NOPAT Less CapEx to Interest Expense	-21,905.27	-625.17	-637.36	-7.11	-1.69	-14.92	-42.61	-30.81	-14.15	-33.87
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Exact Sciences' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	14.61%	16.71%	23.82%	19.26%	20.12%	16.98%	5.82%	12.41%	12.78%	10.29%
EBITDA Growth	12.83%	59.34%	78.82%	76.59%	160.26%	81.78%	-70.16%	200.95%	-74.00%	-5,922.42%
EBIT Growth	9.49%	43.77%	56.81%	52.89%	104.67%	45.52%	-30.34%	65.87%	-675.31%	-1,191.77%
NOPAT Growth	14.79%	46.32%	56.44%	51.79%	105.40%	42.93%	-38.40%	65.87%	-629.01%	-1,191.77%
Net Income Growth	10.89%	42.09%	59.02%	51.21%	100.53%	61.04%	-48.65%	80.49%	-4,915.62%	-1,637.30%
EPS Growth	13.40%	44.62%	0.00%	52.13%	100.00%	0.00%	0.00%	80.00%	0.00%	0.00%
Operating Cash Flow Growth	-0.37%	311.77%	78.01%	264.86%	159.52%	33.65%	-115.39%	6.61%	469.43%	-32.33%
Free Cash Flow Firm Growth	84.52%	96.33%	63.13%	1,075.71%	1,598.38%	-33.25%	2.06%	-204.66%	-202.34%	269.53%
Invested Capital Growth	4.91%	0.00%	2.39%	0.00%	0.00%	1.31%	1.84%	0.00%	0.00%	-16.38%
Revenue Q/Q Growth	0.27%	5.72%	8.94%	3.26%	1.00%	2.95%	0.00%	9.68%	1.34%	0.67%
EBITDA Q/Q Growth	13.32%	23.49%	63.55%	3.14%	323.11%	-123.13%	0.00%	157.46%	-42.53%	-5,456.61%
EBIT Q/Q Growth	10.20%	15.09%	38.09%	0.21%	108.90%	-1,090.52%	0.00%	73.87%	-50.07%	-2,124.07%
NOPAT Q/Q Growth	13.49%	13.89%	35.15%	0.21%	109.68%	-1,010.81%	0.00%	75.39%	-50.07%	-2,124.07%
Net Income Q/Q Growth	10.42%	14.13%	41.95%	-9.27%	100.98%	-6,367.76%	0.00%	85.66%	-141.88%	-2,161.18%
EPS Q/Q Growth	10.64%	14.29%	0.00%	0.00%	100.00%	0.00%	0.00%	0.00%	-133.33%	0.00%
Operating Cash Flow Q/Q Growth	32.82%	227.15%	-173.44%	362.79%	-75.74%	185.49%	0.00%	230.07%	29.57%	-66.07%
Free Cash Flow Firm Q/Q Growth	34.08%	74.21%	-102.55%	2,933.26%	1.24%	-102.29%	0.00%	-2,927.75%	1.01%	103.80%
Invested Capital Q/Q Growth	0.00%	0.00%	1.83%	-100.00%	0.00%	0.00%	0.00%	-0.57%	-1.20%	-16.85%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	71.72%	57.66%	73.96%	74.76%	73.18%	60.55%	73.32%	72.85%	72.33%	60.17%
EBITDA Margin	-18.75%	-13.57%	-4.54%	-4.26%	9.41%	-2.11%	-7.30%	3.82%	2.17%	-115.39%
Operating Margin	-26.39%	-21.50%	-12.80%	-12.37%	1.09%	-10.49%	-16.74%	-3.75%	-5.56%	-122.84%
EBIT Margin	-28.03%	-22.52%	-12.80%	-12.37%	1.09%	-10.49%	-15.76%	-3.75%	-5.56%	-122.84%
Profit (Net Income) Margin	-28.44%	-23.10%	-12.31%	-13.02%	0.13%	-7.69%	-17.29%	-2.26%	-5.40%	-121.19%
Tax Burden Percent	97.95%	98.32%	102.29%	101.39%	76.13%	98.79%	101.67%	110.20%	102.16%	98.70%
Interest Burden Percent	103.57%	104.34%	94.04%	103.89%	15.23%	74.26%	107.91%	54.63%	94.99%	99.96%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	23.87%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-7.85%	-6.49%	-4.05%	0.00%	0.00%	-3.77%	-5.98%	-2.76%	-4.26%	-52.81%
ROIC Less NNEP Spread (ROIC-NNEP)	-11.41%	-8.99%	-5.26%	0.00%	0.00%	-3.90%	-7.92%	-2.47%	-5.51%	-67.42%
Return on Net Nonoperating Assets (RNNOA)	-5.15%	-5.28%	-2.76%	0.00%	0.00%	-2.23%	-4.65%	-1.38%	-2.93%	-41.77%
Return on Equity (ROE)	-13.00%	-11.77%	-6.81%	0.00%	0.00%	-6.00%	-10.63%	-4.14%	-7.19%	-94.58%
Cash Return on Invested Capital (CROIC)	-15.12%	-8.60%	-9.47%	0.00%	0.00%	-4.40%	-5.27%	-205.45%	-206.83%	1.50%
Operating Return on Assets (OROA)	-8.73%	-7.54%	-4.36%	0.00%	0.00%	-4.13%	-6.24%	-1.47%	-2.22%	-54.66%
Return on Assets (ROA)	-8.85%	-7.73%	-4.19%	0.00%	0.00%	-3.03%	-6.85%	-0.88%	-2.15%	-53.93%
Return on Common Equity (ROCE)	-13.00%	-11.77%	-6.81%	0.00%	0.00%	-6.00%	-10.63%	-4.14%	-7.19%	-94.58%
Return on Equity Simple (ROE_SIMPLE)	-23.54%	0.00%	-16.56%	0.00%	0.00%	0.00%	-7.67%	-5.48%	-6.67%	0.00%
Net Operating Profit after Tax (NOPAT)	-97	-83	-54	-54	5.21	-47	-75	-18	-28	-613
NOPAT Margin	-18.48%	-15.05%	-8.96%	-8.66%	0.83%	-7.34%	-11.71%	-2.63%	-3.89%	-85.99%
Net Nonoperating Expense Percent (NNEP)	3.55%	2.49%	1.21%	0.00%	0.00%	0.13%	1.94%	-0.29%	1.25%	14.61%
Return On Investment Capital (ROIC_SIMPLE)	-	-1.52%	-	-	-	-0.84%	-	-	-	-11.96%
Cost of Revenue to Revenue	28.28%	42.34%	26.04%	25.24%	26.82%	39.45%	26.68%	27.15%	27.67%	39.83%
SG&A Expenses to Revenue	36.70%	21.69%	36.07%	38.25%	34.60%	19.73%	38.13%	28.87%	30.65%	16.77%
R&D to Revenue	17.36%	17.19%	15.84%	16.73%	17.74%	17.93%	17.35%	17.29%	14.13%	13.96%
Operating Expenses to Revenue	98.11%	79.16%	86.76%	87.13%	72.09%	71.04%	90.05%	76.61%	77.89%	183.01%
Earnings before Interest and Taxes (EBIT)	-147	-125	-77	-77	6.85	-68	-100	-26	-39	-876
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-98	-75	-27	-26	59	-14	-47	27	15	-823
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.89	2.89	3.87	0.00	0.00	4.25	3.99	2.44	3.92	4.33
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.87	4.22	5.49	7.36	5.12	5.35	4.93	2.98	4.68	3.77
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.56	2.19	2.82	0.00	0.00	3.09	2.87	1.92	2.91	2.95
Enterprise Value to Revenue (EV/Rev)	3.76	5.08	6.31	0.00	0.00	6.05	5.67	3.67	5.31	4.38
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	493.37	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	96.89	128.24	80.77	61.35	57.42
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	179.52
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.79	0.79	0.81	0.00	0.00	0.80	0.81	0.86	0.85	1.14
Long-Term Debt to Equity	0.79	0.79	0.80	0.00	0.00	0.79	0.71	0.78	0.77	1.03
Financial Leverage	0.45	0.59	0.52	0.00	0.00	0.57	0.59	0.56	0.53	0.62
Leverage Ratio	1.98	2.05	2.02	0.00	0.00	2.05	2.05	2.09	2.10	2.24
Compound Leverage Factor	2.05	2.14	1.90	0.00	0.00	1.52	2.21	1.14	2.00	2.23
Debt to Total Capital	44.28%	44.28%	44.78%	0.00%	0.00%	44.53%	44.66%	46.14%	45.97%	53.17%
Short-Term Debt to Total Capital	0.00%	0.00%	0.88%	0.00%	0.00%	0.88%	5.28%	4.20%	4.19%	4.86%
Long-Term Debt to Total Capital	44.28%	44.28%	43.90%	0.00%	0.00%	43.65%	39.38%	41.94%	41.78%	48.31%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	55.72%	55.72%	55.22%	0.00%	0.00%	55.47%	55.34%	53.86%	54.03%	46.83%
Debt to EBITDA	-4.73	-5.82	-8.56	0.00	0.00	-300.49	-74.78	140.77	-112.35	-3.43
Net Debt to EBITDA	-3.50	-4.30	-6.08	0.00	0.00	-207.96	-55.49	92.03	-70.35	-2.13
Long-Term Debt to EBITDA	-4.73	-5.82	-8.39	0.00	0.00	-294.54	-65.94	127.95	-102.11	-3.12
Debt to NOPAT	-4.96	-5.82	-7.33	0.00	0.00	-16.78	-14.76	-20.14	-16.24	-3.72
Net Debt to NOPAT	-3.67	-4.30	-5.20	0.00	0.00	-11.61	-10.96	-13.17	-10.17	-2.30
Long-Term Debt to NOPAT	-4.96	-5.82	-7.18	0.00	0.00	-16.45	-13.02	-18.31	-14.76	-3.38
Altman Z-Score	0.70	1.30	1.88	0.00	0.00	2.14	1.95	1.11	1.90	0.85
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.38	2.38	2.41	0.00	0.00	2.32	1.64	2.17	2.12	2.15
Quick Ratio	1.91	1.91	1.96	0.00	0.00	1.91	1.30	1.81	1.78	1.76
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-323	-83	-169	4,776	4,835	-111	-165	-4,998	-4,948	188
Operating Cash Flow to CapEx	-91.69%	71.40%	-130.16%	289.23%	96.72%	196.34%	-218.63%	298.51%	530.31%	57.88%
Free Cash Flow to Firm to Interest Expense	-61.64	-15.38	0.00	610.87	614.26	-14.10	-20.78	0.00	-515.06	19.63
Operating Cash Flow to Interest Expense	-7.82	9.62	0.00	12.85	3.10	8.84	-10.36	0.00	14.44	4.91
Operating Cash Flow Less CapEx to Interest Expense	-16.34	-3.85	0.00	8.40	-0.10	4.34	-15.10	0.00	11.72	-3.58
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.31	0.33	0.34	0.00	0.00	0.39	0.40	0.39	0.40	0.45
Accounts Receivable Turnover	9.84	13.19	10.86	0.00	0.00	13.82	11.52	9.90	10.17	12.19
Inventory Turnover	5.12	5.59	4.85	0.00	0.00	6.00	5.11	5.50	5.31	5.80
Fixed Asset Turnover	3.32	3.04	3.35	0.00	0.00	3.61	3.64	3.72	3.90	3.96
Accounts Payable Turnover	9.37	8.83	8.52	0.00	0.00	9.60	9.96	13.22	7.45	9.98
Days Sales Outstanding (DSO)	37.10	27.68	33.60	0.00	0.00	26.40	31.68	36.87	35.90	29.94
Days Inventory Outstanding (DIO)	71.30	65.27	75.20	0.00	0.00	60.80	71.46	66.38	68.69	62.96
Days Payable Outstanding (DPO)	38.96	41.35	42.84	0.00	0.00	38.04	36.65	27.61	48.97	36.58
Cash Conversion Cycle (CCC)	69.44	51.60	65.95	0.00	0.00	49.17	66.49	75.64	55.63	56.33
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	4,830	4,830	4,918	0.00	0.00	4,893	5,009	4,980	4,921	4,092
Invested Capital Turnover	0.43	0.43	0.45	0.00	0.00	0.51	0.51	1.05	1.09	0.61
Increase / (Decrease) in Invested Capital	226	0.00	115	-4,830	-4,830	63	90	4,980	4,921	-801
Enterprise Value (EV)	7,536	10,584	13,882	0.00	0.00	15,127	14,365	9,584	14,297	12,089
Market Capitalization	5,749	8,797	12,085	16,938	12,325	13,379	12,489	7,796	12,587	10,399
Book Value per Share	$17.20	$17.13	$17.51	$0.00	$0.00	$17.39	$17.18	$17.30	$17.38	$12.98
Tangible Book Value per Share	($7.12)	($7.09)	($6.50)	$0.00	$0.00	($6.15)	($6.04)	($5.52)	($5.53)	($5.26)
Total Capital	5,462	5,462	5,653	0.00	0.00	5,671	5,661	5,927	5,942	5,130
Total Debt	2,419	2,419	2,531	0.00	0.00	2,525	2,528	2,735	2,731	2,727
Total Long-Term Debt	2,419	2,419	2,481	0.00	0.00	2,475	2,229	2,486	2,482	2,478
Net Debt	1,786	1,786	1,797	0.00	0.00	1,748	1,876	1,788	1,710	1,689
Capital Expenditures (CapEx)	45	73	29	35	25	35	38	36	26	81
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-63	-63	-13	0.00	0.00	-48	82	86	37	50
Debt-free Net Working Capital (DFNWC)	570	570	722	0.00	0.00	730	734	1,033	1,058	1,088
Net Working Capital (NWC)	570	570	672	0.00	0.00	680	435	784	809	839
Net Nonoperating Expense (NNE)	52	45	20	27	4.42	2.28	36	-2.57	11	251
Net Nonoperating Obligations (NNO)	1,786	1,786	1,797	0.00	0.00	1,748	1,876	1,788	1,710	1,689
Total Depreciation and Amortization (D&A)	49	49	50	50	52	54	54	53	55	53
Debt-free, Cash-free Net Working Capital to Revenue	-3.12%	-3.00%	-0.58%	0.00%	0.00%	-1.92%	3.23%	3.29%	1.39%	1.83%
Debt-free Net Working Capital to Revenue	28.40%	27.32%	32.80%	0.00%	0.00%	29.19%	28.96%	39.54%	39.32%	39.45%
Net Working Capital to Revenue	28.40%	27.32%	30.53%	0.00%	0.00%	27.19%	17.17%	30.01%	30.07%	30.42%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.84)	($0.72)	$0.00	$0.00	$0.00	($0.26)	($0.60)	($0.09)	($0.21)	($4.69)
Adjusted Weighted Average Basic Shares Outstanding	177.00M	176.35M	0.00	0.00	0.00	180.14M	182.35M	184.31M	184.80M	184.20M
Adjusted Diluted Earnings per Share	($0.84)	($0.72)	$0.00	$0.00	$0.00	$0.00	$0.00	($0.09)	($0.21)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	177.00M	176.35M	0.00	0.00	0.00	180.14M	184.53M	184.31M	184.80M	184.20M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	177.68M	0.00	0.00	0.00	0.00	181.53M	184.53M	184.77M	185.08M	185.76M
Normalized Net Operating Profit after Tax (NOPAT)	-92	-81	-54	-53	5.21	-47	-72	-13	-14	-27
Normalized NOPAT Margin	-17.68%	-14.61%	-8.95%	-8.59%	0.83%	-7.34%	-11.23%	-1.81%	-2.05%	-3.75%
Pre Tax Income Margin	-29.04%	-23.50%	-12.03%	-12.85%	0.17%	-7.79%	-17.01%	-2.05%	-5.28%	-122.78%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-28.01	-23.02	0.00	-9.84	0.87	-8.63	-12.65	0.00	-4.10	-91.51
NOPAT to Interest Expense	-18.46	-15.38	0.00	-6.89	0.66	-6.04	-9.40	0.00	-2.87	-64.05
EBIT Less CapEx to Interest Expense	-36.54	-36.49	0.00	-14.28	-2.33	-13.13	-17.39	0.00	-6.82	-100.00
NOPAT Less CapEx to Interest Expense	-26.99	-28.85	0.00	-11.33	-2.54	-10.54	-14.14	0.00	-5.59	-72.54
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Exact Sciences' Financials

When does Exact Sciences's fiscal year end?

According to the most recent income statement we have on file, Exact Sciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Exact Sciences' net income changed over the last 9 years?

Exact Sciences' net income appears to be on an upward trend, with a most recent value of -$1.03 billion in 2024, rising from -$157.80 million in 2015. The previous period was -$204.15 million in 2023. See Exact Sciences' forecast for analyst expectations on what’s next for the company.

What is Exact Sciences's operating income?

Exact Sciences's total operating income in 2024 was -$1.05 billion, based on the following breakdown:

Total Gross Profit: $1.92 billion
Total Operating Expenses: $2.97 billion

How has Exact Sciences revenue changed over the last 9 years?

Over the last 9 years, Exact Sciences' total revenue changed from $39.44 million in 2015 to $2.76 billion in 2024, a change of 6,895.6%.

How much debt does Exact Sciences have?

Exact Sciences' total liabilities were at $3.53 billion at the end of 2024, a 6.0% increase from 2023, and a 9,384.8% increase since 2015.

How much cash does Exact Sciences have?

In the past 9 years, Exact Sciences' cash and equivalents has ranged from $41.14 million in 2015 to $1.49 billion in 2020, and is currently $600.89 million as of their latest financial filing in 2024.

How has Exact Sciences' book value per share changed over the last 9 years?

Over the last 9 years, Exact Sciences' book value per share changed from 3.39 in 2015 to 12.98 in 2024, a change of 282.6%.

Related Companies

This page (NASDAQ:EXAS) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exact Sciences (EXAS) Financials

Frequently Asked Questions About Exact Sciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exact Sciences (EXAS) Financials

Annual Income Statements for Exact Sciences

Quarterly Income Statements for Exact Sciences

Annual Cash Flow Statements for Exact Sciences

Quarterly Cash Flow Statements for Exact Sciences

Annual Balance Sheets for Exact Sciences

Quarterly Balance Sheets for Exact Sciences

Annual Metrics and Ratios for Exact Sciences

Quarterly Metrics and Ratios for Exact Sciences

Frequently Asked Questions About Exact Sciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools